Indoco Remedies Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/2idc0dmhf8rsocnbaxr662vx.pdf

Key Takeaways


Master Manufacturing Overhaul

Aditi Panandikar: "we have made a plan which will allow us to ride through these kinds of rough phases. And therefore, you may say it is voluntary, but we feel it is mandatory, if we are to going-forward show better efficiency and..."

USFDA & Goa Plant 2 Remediation


US Business & FPP Transition


Domestic & OTC Transformation

Aditi Panandikar: "You know, if I were you, I would concentrate on growth in sales because we have one OTC because the whole thing about doing OTC is getting a much larger market from which to get share. And while this expenditure initially is like an investment and we should be prepared for that."

Margins & Cost Structure

Aditi Panandikar: "And I would not like to unnecessarily commit, but I'm actually hoping that as the numbers come out, you will see the beauty of what this kind of restructuring does..."

Balance Sheet & Capex

Aditi Panandikar: "So it might appear to you right now that the company is investing when it may not have required these investments. But trust me that the investments that are being done now are to prepare for a time when the huge volumes..."

Guidance & Commitments

CommitmentSpecificsTimeline
Remediation completionGoa Plant 2 remediation to be fully finishedQ3 FY25
Europe ramp-upFull supply ramp-up from European siteQ3 FY25
Sequential improvementQ3 revenue to improve over Q2, driven by Europe completion and solid oral ramp-upQ3 FY25
Smooth operations upsideMeaningful upside visible from smooth plant functioningQ4 FY25
FPP drain reductionCorporate-level drain from Florida Pharma to come downWithin six months of smooth US supply start
Capex moderationNo significant incremental capex beyond ~₹200 crore program; future limited to maintenance plus intermittent ₹40-50 croreRemaining six months and beyond
Warren Remedies capex completionAPI finished goods lines capex to finishWithin six months
Normalized operationsAll things expected to come in lineAfter April 2025

Key Metrics

MetricQ2 FY25
Net revenue₹394.6 cr, compared to ₹394.2 cr in the immediate preceding quarter
EBITDA margin13.4%, compared to 15.6% in the same quarter last year
EBITDA₹52.9 cr, compared to ₹72.4 cr in the same quarter last year
PAT margin3.2% (per an analyst's math), compared to 8.4% in the same quarter last year
PAT₹12.8 cr, compared to ₹33.1 cr in the same quarter last year
EPS₹1.39, compared to ₹3.59 in the same quarter last year
Domestic formulation revenue₹234.6 cr, grew 2.9% YoY from ₹228.1 cr
International business revenue₹126.2 cr, compared to ₹194.9 cr in the same quarter last year
US business revenue₹24.7 cr, compared to ₹81.4 cr in the same quarter last year
Europe revenue₹59.9 cr, compared to ₹63.4 cr in the same quarter last year
Emerging markets revenue₹39.6 cr, compared to ₹45.4 cr in the same quarter last year
API business revenue₹30.1 cr, compared to ₹35.8 cr in the same quarter last year
AnaCipher CRO and Indoco Analytical Solutions revenue₹3.6 cr, compared to ₹6.4 cr in the same quarter last year
Capex incurred (H1 FY25)₹220 cr
Full-year capex guidance₹200+ cr, with ₹180-odd cr already incurred in H1
Pending ANDAs with USFDA~25, of which ~6 are solid orals and the rest are sterile
OTC toothpaste expected revenue (FY25)In excess of ₹120 cr, up from ₹85-90 cr when in ethical